DEA No. 2316
DEA No. 2316 Brand names, DEA No. 2316 Analogs
- (+/-)-Secobarbital
- Barbosec
- Bipanal
- Bipinal sodium
- DEA No. 2315
- DEA No. 2316
- Evronal
- Evronal Sodium
- Evrronal
- Hypotrol
- Hyptran
- Imesonal
- Immenoctal
- Immenox
- Meballymal
- Meballymal sodium
- Meballymalum
- Novosecobarb
- Pramil
- Quinalbarbital
- Quinalbarbitone
- Quinalbarbitone sodium
- Quinalspan
- Sebar
- Seco 8
- Secobarbital (USP)
- Secobarbital Sodium
- Secobarbital [USAN:INN]
- Secobarbital suppository dosage form
- Secobarbitale [DCIT]
- Secobarbitalum [INN-Latin]
- Secobarbitone
- Seconal
- Seconal (TN)
- Seconal Sodium
- Sedutain
- Seotal
- Sodium Secobarbital
- Sodium Seconal
- Sodium quinalbarbitone
- Somosal
- Synate
- Trisomnin
DEA No. 2316 Brand Names Mixture
- No information avaliable
DEA No. 2316 Chemical_Formula
C12H18N2O3
DEA No. 2316 RX_link
No information avaliable
DEA No. 2316 fda sheet
DEA No. 2316 msds (material safety sheet)
DEA No. 2316 Synthesis Reference
No information avaliable
DEA No. 2316 Molecular Weight
238.283 g/mol
DEA No. 2316 Melting Point
100 oC
DEA No. 2316 H2O Solubility
550 mg/L
DEA No. 2316 State
Solid
DEA No. 2316 LogP
1.879
DEA No. 2316 Dosage Forms
Capsule
DEA No. 2316 Indication
For the Short-term treatment of intractable insomnia for patients habituated to barbiturates
DEA No. 2316 Pharmacology
Secobarbital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
DEA No. 2316 Absorption
No information avaliable
DEA No. 2316 side effects and Toxicity
No information avaliable
DEA No. 2316 Patient Information
No information avaliable
DEA No. 2316 Organisms Affected
Humans and other mammals
